Navigation Links
Vanderbilt Medical Center chosen as Evidence-based Practice Center
Date:10/10/2007

Vanderbilt University Medical Center has been chosen as one of 14 Evidence-based Practice Centers (EPCs) in the United States and Canada, the Agency for Healthcare Research and Quality (AHRQ) announced today.

For a decade AHRQ has systematically reviewed and reported on the content and quality of the medical literature on specific topics like choice of depression treatments, prostate cancer screening options, and surgical outcomes for knee replacement. The groups that conduct the reviews and summarize the implications are called the Evidence-based Practice Centers.

EPCs evaluate the state of the science of specified scientific topics by performing methodologically rigorous systematic reviews and analyses of scientific literature, making options more clear for patients with complex or life-threatening diagnoses who face a bewildering array of information and treatment options, for doctors who must consider new reports of possible harms for treatments that have been mainstays, and for payers who have to weigh the potential benefits and costs of coverage of new drugs, procedures, and diagnostic tests.

EPC topics encompass clinical, preventive, behavioral, organizational and financial aspects of health care. Ancillary analyses, such as claims data analyses or use of advanced models to demonstrate potential outcomes of alternatives, are also performed by EPCs. The end result is a combination of existing knowledge termed an Evidence Report. These reports, which Vanderbilt will now play a leading role in writing, are used by groups including federal and state agencies, private sector professional societies, health delivery systems, providers and payers.

This five-year designation as an EPC recognizes the unique strengths of VUMC -- few other academic medical centers have systems as strong for linking medical care, informatics, training and evidence-based medicine resources to rapidly move best evidence into clinical practice.
'/>"/>

Contact: Craig Boerner
craig.boerner@vanderbilt.edu
615-322-4747
Vanderbilt University Medical Center
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related medicine news :

1. Vanderbilt-Ingram Cancer Center To Study Ways To Prevent Chemo Brain
2. Vanderbilt Performs States First Stem Cell Heart Regeneration Therapy
3. Check if your “Favourite medical web-site” is indulging in Quackey
4. Teens turning to Internet for medical queries
5. Robots craft medical history
6. NBE to conduct test for medical students from abroad
7. Air pollution combined with greater medical needs
8. Indian Nationals with Foreign Medical Degrees can now practice in India
9. Children! Protecting them from medical mistakes
10. More information sought by patients on medical errors
11. SARS necessitates medical masks
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10DSS Research Announces Senior Health Risk Assessment 28SrHRA 29 28TM 29 58537 1DSS Research Announces Senior Health Risk Assessment 28SrHRA 29 28TM 29 58537 2Pan American Life Insurance Group Plans to Complete Coverage in Central America With Entry Into Costa Rica 3B Company Files Request for Authorization 58534 1Pan American Life Insurance Group Plans to Complete Coverage in Central America With Entry Into Costa Rica 3B Company Files Request for Authorization 58534 2Sport Science Lab Maintains That Injury to USC Football Player is Symptomatic of the Dangers of Conventional Weight Training 58530 1Sport Science Lab Maintains That Injury to USC Football Player is Symptomatic of the Dangers of Conventional Weight Training 58530 2